Orserdu (elacestrant) gets FDA approval for treatment of estrogen-receptor positive metastatic breast cancer. by Dr. C.H. Weaver M.D. [Updated 2/2023]
Orserdu (elacestrant) is a selective estrogen receptor degrader – a novel orally administered medication approved by the US Food and Drug Administration in January 2023 for the treatment of estrogen-receptor positive metastatic breast cancer.
Metastatic breast cancer (MBC) remains the second leading cause of cancer death in women in the United States.
The majority of breast cancers are estrogen receptor positive (ER+) and respond to treatment with medications that block the effect of estrogen on breast cancer cells.
The mainstay of treatment of ER+ breast cancers is endocrine therapy, which currently includes selective estrogen receptor modulators (SERMs), aromatase inhibitors (AIs), and the selective estrogen receptor degrader (SERD) Faslodex (fulvestrant).
Endocrine therapy is recommended over chemotherapy for first-line treatment of ER+ MBC in most cases except in the rare setting of visceral crisis.